Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | ARG1 | P05089 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587534 | 0.86 | ALDH1A1 (0.34) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL4587770 | 0.83 | MAPT (0.36) | PTGS2 | |
| SCHEMBL4588053 | 0.82 | GLO1 (0.35) | BHMTPTGS1 | |
| SCHEMBL4588714 | 0.81 | NOS2 (0.33) | BHMTNOS2NOS1NOS3ARG1 | |
| SCHEMBL5150879 | 0.78 | CYP1A2 (0.36) | BHMTNOS1PTGS1PTGS2 | |
| SCHEMBL4587098 | 0.78 | ARG1 (0.33) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL4587151 | 0.77 | NOS2 (0.33) | NOS2NOS1NOS3ARG1ARG2 | |
| SCHEMBL4586374 | 0.76 | TLR2 (0.32) | ARG1ARG2 | |
| SCHEMBL4618533 | 0.75 | PTGS1 (0.33) | ARG1ARG2PTGS1PTGS2 | |
| SCHEMBL4587301 | 0.74 | ARG1 (0.35) | NOS2NOS1NOS3ARG1ARG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | BHMT 746/4885NOS2 5/4885NOS1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.